82 related articles for article (PubMed ID: 29034308)
1. Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand.
Termrungruanglert W; Khemapech N; Tantitamit T; Sangrajrang S; Havanond P; Laowahutanont P
Gynecol Oncol Rep; 2017 Nov; 22():58-63. PubMed ID: 29034308
[TBL] [Abstract][Full Text] [Related]
2. A Model Approach for Assessing the Benefits of HPV Testing against Cytology in Screening for Cervical Cancer Precursors in Thailand.
Tantitamit T; Termrungruanglert W; Khemapech N; Havanond P
Asian Pac J Cancer Prev; 2017 May; 18(5):1271-1275. PubMed ID: 28610413
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
[TBL] [Abstract][Full Text] [Related]
4. HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile.
Lagos M; Van De Wyngard V; Poggi H; Cook P; Viviani P; Barriga MI; Pruyas M; Ferreccio C
Infect Agent Cancer; 2015; 10():43. PubMed ID: 26600869
[TBL] [Abstract][Full Text] [Related]
5. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
6. Implementation of primary HPV testing in Japan.
Kurokawa T; Yoshida Y; Iwanari O; Oishi T; Kasai T; Hamada M; Fujita H; Fujiwara H; Yokoyama M; Sakuragi N; Kigawa J; Suzuki M
Mol Clin Oncol; 2020 Oct; 13(4):22. PubMed ID: 32765870
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
8. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
9. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
14. The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.
Kurokawa T; Onuma T; Shinagawa A; Chino Y; Kobayashi M; Yoshida Y
Cytopathology; 2018 Aug; 29(4):361-367. PubMed ID: 29768678
[TBL] [Abstract][Full Text] [Related]
15. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Srisomboon J; Intaraphet S; Siriaunkgul S
PLoS One; 2016; 11(6):e0158184. PubMed ID: 27336913
[TBL] [Abstract][Full Text] [Related]
16. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Melnikow J; Henderson JT; Burda BU; Senger CA; Durbin S; Weyrich MS
JAMA; 2018 Aug; 320(7):687-705. PubMed ID: 30140883
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]